Improved risk-benefit ratio for topical triamcinolone acetonide in TransfersomeR in comparison with equipotent cream and ointment: a randomized controlled trial

Fesq, Heike; Lehmann, Jens; Kontny, A.; Erdmann, I.M.; Theiling, K.; Rother, M.; Ring, Johannes; Cevc, Gregor; Abeck, Dietrich

doi:10.1046/j.1365-2133.2003.05475.x

Cited by 61 publications

(21 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding topical treatment, only transfersomes [99], antipsoriatic dithranol liposomes [46] and intraarticular clodronate liposomes for the treatment of RA [33] have entered the clinic. Regarding systemic treatment, it is mainly the work by Mizushima et al on lipid microspheres that has reached the clinic [100,101].…”

Section: Expert Opinionmentioning

confidence: 99%

Liposomes in the treatment of inflammatory disorders

Metselaar

Storm

2005

Expert Opinion on Drug Delivery

113

View full text Add to dashboard Cite

This review focuses on the therapeutic utility of liposomes in the treatment of inflammatory disorders, and aims to offer the reader an overview of the in vivo results obtained with liposomally encapsulated anti-inflammatory and immune suppressive drugs. The past 30 years has clearly indicated the added value of liposomes in the search for solutions for the delivery problems encountered. However, only a few liposomal anti-inflammatory therapeutics have entered the clinic. Reasons for the hurdles existing in the translation of promising preclinical findings to clinical studies are discussed.

show abstract

Section: Expert Opinionmentioning

confidence: 99%

Liposomes in the treatment of inflammatory disorders

Metselaar

Storm

2005

Expert Opinion on Drug Delivery

113

View full text Add to dashboard Cite

show abstract

“…A clinical trial, involving triamcinolone acetonide formulated in second generation lipid vesicles (transferosomes) reported the vesicular formulation to be bioequivalent to commercial formulations (cream and ointment) containing a higher dose of the glucocorticoteroid (10% more). The findings of this study suggest that the use of transfersomoes may improve the risk-benefit ratio of topical glucocorticosteroids compared to conventional vehicles [60].…”

Section: Liposomesmentioning

confidence: 75%

Topical Dermatological Drug Delivery: Quo Vadis?

Akomeah

2010

CDD

View full text Add to dashboard Cite

Skin disease (dermatological conditions') affects at least one-third of the US population and has been cited as one of the top 15 medical conditions for which prevalence and healthcare spending increased in the last decade. The outcome of topical dermatological drug treatment is significantly influenced by the choice of vehicle or delivery system. Advancements in the life sciences coupled with a growing market for dermatologicals have facilitated the emergence of improved topical formulations and drug delivery systems. The current and emerging approaches of optimizing the topical delivery of dermatological agents (small and large molecules) include the use of chemical enhancers, bio-polymers (e.g. sodium hyaluronate), liposomes, particulate carriers (microspheres and lipid nanoparticles), topical sprays and foams, occlusion (via dressings and patches) topical peels, temperature (heat), iontophoresis and ultrasound. These delivery approaches (when used solely or in a synergistic manner) are a significant improvement over conventional systems (creams, lotions, ointments and pastes) and have the potential to enhance efficacy and tolerability, improve patient compliance (including dermatology life quality), and also fulfil other unmet needs of the topical dermatological market.

show abstract

“…In another study performed by Fesq et al [70], the efficacy of transfersomes was compared with commercially available cream and ointment formulations of TA in humans. According to the results of this study, 10-fold lower dose of TA in transfersome was found bioequivalent to conventional formulations as measured by erythema suppression.…”

Section: Formulations Of Tcmentioning

confidence: 99%